Oxyntomodulin long-acting (Pharmsynthez/Xenetic Biosciences)

N/A

Report date: 2022/03/28 14:35:09

Base Information

Drug NameOxyntomodulin long-acting (Pharmsynthez/Xenetic Biosciences)
Drug Alias NameOxyntolongPSA-oxyntomodulin
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionGlucagon receptor agonistsGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptorGlucagon receptor
Therapy Area/IndicationsObesityDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryRussian Federation
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesXenetic Biosciences IncPharmsynthez
China Registration ClassN/A

Develop Information

Active CompaniesPharmsynthezXenetic Biosciences Inc
Inactive CompaniesN/A
Active IndicationsObesityDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A